The European Medicines Agency has recommended revoking the marketing authorization for Amgen’s rare-disease drug Tavneos, citing “incorrect and misleading” clinical data. The action escalates a long-running controversy around the therapy and increases near-term uncertainty for Amgen’s EU commercial position. The recommendation signals that regulators are scrutinizing the underlying evidence package, not only manufacturing or labeling claims. For stakeholders, it raises the likelihood of reimbursement disruptions and shifts in how clinicians manage treatment decisions in the region. Amgen’s next step would typically involve responding to the regulator’s position and awaiting further procedural outcomes, but the EMA recommendation already marks a materially negative regulatory development.